New combination therapy for pancreatic carcinomas and colon cancer

The current invention is based on combination therapies of nucleoside analogs with inhibitors of either the Nodal/Activin pathway or the mTOR / hedgehog pathway and show a remarkable capacity to eliminate cancer stem cells

and to subsequently inhibit pancreatic and/or colon cancer.

Further Information: PDF

Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0

Contact
Peer Biskup

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All news from this category: Technology Offerings

Back to the Homepage

Comments (0)

Write comment

Latest posts

Acute itching in eczema patients linked to environmental allergens

Newly identified pathway explains why antihistamine drugs often don’t work to control severe itch. In addition to a skin rash, many eczema sufferers also experience chronic itching, but sometimes that…

Simulating evolution to understand a hidden switch

Computer simulations of cells evolving over tens of thousands of generations reveal why some organisms retain a disused switch mechanism that turns on under severe stress, changing some of their…

How cells move and don’t get stuck

Cell velocity, or how fast a cell moves, is known to depend on how sticky the surface is beneath it, but the precise mechanisms of this relationship have remained elusive…

Partners & Sponsors

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close